Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Drug Combinations in Advanced Esophageal Squamous Cell Carcinoma
NCT03736863Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib, camrelizumab, adebrelimab and ruzaltatug rezetecan in Esophageal Squamous Cell Carcinoma (ESCC) (4 cohorts), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Objective Response Rate up to 1 year. Started Dec 2019; status: recruiting.
02
Drugs
Rivoceranibcamrelizumabadebrelimabruzaltatug rezetecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03736863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736863.